Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).

结合两个独特的人工智能平台来发现新的基因治疗靶点

• 批准号: 10090332
• 金额: $ 48.26万
• 依托单位: AMPLY DISCOVERY LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10090332
• 关键词: Combining; two; unique; AI; platforms

This project is focused on the discovery of first-in-class drug candidates for the treatment of Acute Myeloid Leukaemia (AML) based on a novel approach to identifying novel genetic targets.AML is a high-risk hematologic malignancy with a high unmet need. Limited treatment options exist, particularly for patients who are ineligible for intensive chemotherapy or experience relapse. AML is rare, making up around 1% of all cancers. In the UK around 3,100 patients will be diagnosed with AML in 2023 (CRUK). Incidence rates are typically higher for those over 45\. Mortality in older patients is high, around 2,700 patients in the UK will die annually from AML. The 5-year relative survival rate for people over twenty with AML is 28%. Poor outcomes due to drug resistance and relapse is common in patients with AML.This project will combine the unique AI-based bioinformatics platforms and expertise of two SMEs, based in the UK and Switzerland, to tackle the problem of AML using AI, machine learning and synthetic biology to advance new disease understanding, novel target identification, and novel drug discovery.

该项目的重点是基于识别新型遗传靶点的新方法，发现治疗急性髓系白血病（AML）的一流候选药物。AML是一种高风险血液恶性肿瘤，具有高度未满足的需求。有限的治疗选择存在，特别是对于不适合强化化疗或复发的患者。急性粒细胞白血病很少见，约占所有癌症的1%。在英国，2023年将有大约3,100名患者被诊断为AML（CRUK）。45岁以上的人发病率通常较高。老年患者的死亡率很高，英国每年约有2，700名患者死于AML。20岁以上AML患者的5年相对生存率为28%。该项目将结合联合收割机独特的基于人工智能的生物信息学平台和两家位于英国和瑞士的中小企业的专业知识，利用人工智能，机器学习和合成生物学来解决AML问题，以促进新疾病的理解，新靶标的识别和新药的发现。